Preparing before Joining Biopharmaâs Digital Gold Rush Source: D3Damon/Getty Images Timing is key and companies that plan before adopting data-driven biomanufacturing are most likely to succeed. Biopharma is finally starting to show interest in digital manufacturing. The impact of COVID-19 calls for better quality products and continued FDA support for innovative technologies which is helping the normally risk-averse drug industry overcome its conservatism. According to a recent KPMG survey, 44% of 35 biopharmaceutical companies quizzed have implemented data-driven automation in their manufacturing operations. Similarly, in a separate survey by Accenture most of the nearly 1,000 executives who took part identified the âprofitable adoption of new digital technologiesâ as their top priority over the next three years.